Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis

Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi and C. Michael Stein
The Journal of Rheumatology October 2015, 42 (10) 1746-1751; DOI: https://doi.org/10.3899/jrheum.150232
Michelle J. Ormseth
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michelle.ormseth{at}vanderbilt.edu
Joseph F. Solus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasey C. Vickers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette M. Oeser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Raggi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Michael Stein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective. MicroRNA (miRNA) are small noncoding RNA that posttranscriptionally regulate gene expression and serve as potential mediators and markers of disease. Recently, plasma miR-24-3p and miR-125a-5p concentrations were shown to be elevated in rheumatoid arthritis (RA) and useful for RA diagnosis. We assessed the utility of 7 candidate plasma miRNA, selected for biological relevance, for RA diagnosis and use as markers of disease activity and subclinical atherosclerosis in RA.

Methods. The cross-sectional study included 168 patients with RA and 91 control subjects of similar age, race, and sex. Plasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were measured by quantitative PCR. Utility of plasma miRNA concentrations for RA diagnosis was assessed by area under the receiver-operating characteristic curve (AUROC). Associations between plasma miRNA concentrations and RA disease activity and coronary artery calcium score were assessed by Spearman correlations.

Results. Plasma concentrations of miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p were significantly increased in patients with RA. The highest AUROC for diagnosis of RA (AUROC = 0.725) was found in miR-24-3p, including among rheumatoid factor–negative patients (AUROC = 0.772). Among all patients with RA, the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p improved the model modestly (AUROC = 0.747). One miRNA, miR-155-5p, was weakly inversely associated with swollen joint count (p = 0.024), but no other miRNA were associated with disease activity or coronary artery calcium score.

Conclusion. The combination of miR-24-3p, miR-26a-5p, and miR-125a-5p had the strongest diagnostic accuracy for RA. Candidate miRNA had little or no association with RA disease activity or subclinical atherosclerosis.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • MICRORNA
  • ATHEROSCLEROSIS
  • DISEASE ACTIVITY
  • DIAGNOSIS
  • CARDIOVASCULAR RISK

MicroRNA (miRNA) are small (about 22 nucleotides in length) noncoding RNA that bind to 3′ untranslated regions of mRNA and cause destabilization of transcription machinery or transcript degradation1,2,3. Each miRNA has the capacity to bind to many different mRNA transcripts, thus potentially affecting multiple distinct pathways. miRNA are differentially expressed within many cell types and are stable within extracellular fluids such as plasma, where they are protected within exosomes4, microvesicles5, lipoproteins6, and Argonaute2 protein complexes7. The association of miRNA with lipid and protein carriers in plasma confers extraordinary stability8,9. Their stability in plasma and known biological function within cells make them highly relevant to disease mechanisms and ideal candidates for diagnostic tests, disease biomarkers, and therapeutic targets.

Circulating miRNA have great potential as biomarkers in patients with rheumatoid arthritis (RA) to aid in diagnosis and disease activity monitoring, as well as prediction of cardiovascular risk, the main cause of early death in patients with RA10,11. Currently, there is little information regarding plasma miRNA in RA. More is known about cellular miRNA alterations and how these affect important cellular functions in RA. Examples include the role of miR-15a-5p in cellular apoptosis12,13, miR-24-3p in maintenance of autoreactive B cells14, miR-125a-5p and miR-223-3p in macrophage cytokine production15, and miR-26a-5p, miR-146a-5p, and miR-155-5p in interleukin 17 (IL-17)–producing T cells16. Alterations of several of these miRNA, such as miR-146a-5p and miR-155-5p, have been suggested to also play a role in the development of cardiovascular disease in RA17.

One study has reported that miR-24-3p and miR-125a-5p have diagnostic potential for RA18. We hypothesized that these 2 miRNA, along with miR-15a-5p, miR-26a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p, may be useful biomarkers for RA diagnosis and disease activity. Because many of the miRNA with a role in the pathogenesis of RA19 overlap with those implicated in the development of atherosclerosis20,21, we also hypothesized that these miRNA may also serve as biomarkers of subclinical atherosclerosis in patients with RA.

MATERIALS AND METHODS

Study population

This was a cross-sectional study that included 168 patients with RA and 91 control subjects. This cohort is part of a group of patients extensively characterized for cardiovascular risk22. Recruitment and study procedures have been described22. All subjects were older than 18 years of age and patients with RA fulfilled American College of Rheumatology 1987 classification criteria for RA23. RA and control groups were frequency-matched for age, race, and sex and control subjects did not have RA or other inflammatory disease. The study was approved by the Vanderbilt Institutional Review Board and all subjects gave written informed consent.

Clinical and laboratory data

Clinical information and laboratory measurements were obtained as described22. Disease activity of RA was determined by the 28-joint Disease Activity Score (DAS28) using erythrocyte sedimentation rate (ESR) as the marker of inflammation24. Body mass index (BMI) was calculated and expressed as kg/m2. Framingham risk score for 10-year percent risk of a cardiovascular event was determined as described25,26.

Fasting cholesterol panel, ESR, and high-sensitivity C-reactive protein (CRP) were measured by the Vanderbilt University Medical Center Clinical Laboratory or by ELISA (Millipore). The degree of insulin resistance was calculated by the homeostatic model assessment of insulin resistance [HOMA; fasting glucose (mmol/l) × fasting insulin (μU/ml)/22.5]27. Coronary artery calcium score was measured by electron beam computed tomography with an Imatron C-150 scanner (GE/Imatron) as described22 and quantified in Agatston units28.

RNA isolation, cDNA synthesis, and quantitative PCR

Plasma (collected in EDTA-containing tubes) from each subject was stored at −80°C. RNA was extracted from 250 μl of plasma using a total RNA purification kit, in a 96-well format (Norgen). All plasma RNA samples were extracted at the same time. RNA was collected in a total volume of 100 μl in sequential 50 μl elutions. A volume of 5 μl of RNA from each subject was polyadenylated and used for first-strand cDNA synthesis (Quanta Biosciences). The cDNA was diluted 1:20 in Tris-EDTA buffer and stored at −20°C.

All miRNA assays (miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125-5p, miR-146a-5p, miR-155-5p, and miR-223-3p) used 5 μl diluted cDNA in 20 μl final reaction volume (Quanta Biosciences) in a 96-well format on Bio-Rad CFX96 instruments. Cycling conditions consisted of a 3-min incubation at 95°C; 50 cycles of amplification at 95°C for 10 s then 60°C for 30 s; 95°C for 1 min; 55°C for 1 min, followed by an 80-step melt curve in 0.5°C increments from 55°C to 95°C. Technical replicates were performed in triplicate. Proportional numbers of RA and control cDNA samples, a no-cDNA template negative control, and a 4-point, 10-fold dilution standard of whole blood cDNA were included on each of 10 PCR plates for each miRNA assay. Quality control results for the miRNA assays are shown in Supplementary Table 1, available online at jrheum.org.

Quantitative PCR (qPCR) miRNA data were converted to molar concentrations using 1 zeptomole to 1 attomole serial dilution of qPCR miRNA mimics. Single-stranded DNA mimics were synthesized for miR-15a-5p, miR-24-3p, and miR-223-3p, each of which included the universal PCR primer sequence, a 2-base dA spacer, and the reverse complement of the miRNA assay primer sequence (IDT Inc.). Quality control results for the mimic standard dilutions are shown in Supplementary Table 2 (available online at jrheum.org), with nearly identical results for each. A composite curve including the 3 mimic dilution standards was used to convert qPCR data to molar amounts for each miRNA assay. All assays and analyses were done using applicable minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines29.

Statistical methods

Descriptive statistics were calculated as mean ± SD for continuous variables, and frequency and proportions for categorical variables. Wilcoxon rank sum tests were used to compare continuous variables and Pearson’s chi-square test to compare categorical variables.

To determine the utility of plasma miRNA for diagnosis of RA, receiver-operating characteristic (ROC) curves were plotted and area under the curve (AUROC) was calculated for each miRNA. For combinations of miRNA, logistic regression was used with the dependent variable as disease status (RA versus control), and the independent variable as the miRNA of interest. The predicted probability for RA diagnosis determined from the logistic regression was plotted in an ROC curve and AUROC was calculated. Spearman correlation coefficients for continuous variables and Wilcoxon rank sum tests for categorical variables were used to determine the association between plasma miRNA concentrations and variables of interest pertaining to RA disease activity and cardiovascular risk.

Statistical analyses were performed using IBM SPSS Statistics v22. Two-sided p values ≤ 0.05 were considered statistically significant.

RESULTS

Clinical characteristics

As described22,30, clinical characteristics of patients with RA and control subjects are presented in Table 1. Patients and controls were of similar age, race, and sex. Patients with RA had moderate disease activity with a mean DAS28 score of 3.79, and higher CRP than controls (p < 0.001; Table 1). The majority of patients with RA were rheumatoid factor (RF)-positive (69%), and taking methotrexate (MTX; 71%) and prednisone (54%; Table 1). Patients with RA had greater waist circumference and lower low-density lipoprotein cholesterol (LDL-C) than control subjects (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics. Presented as mean ± SD, unless otherwise indicated.

Diagnostic capacity of candidate miRNA for RA

Patients with RA had higher plasma concentrations compared to control subjects of miR-15a-5p (2.7-fold, p < 0.001), miR-24-3p (3.5-fold, p < 0.001), miR-26a-5p (1.8-fold, p < 0.001), miR-125a-5p (1.2-fold, p = 0.003), miR-146a-5p (2.5-fold, p < 0.001), miR-155-5p (2.7-fold, p < 0.001), and miR-223-3p (2.5-fold, p < 0.001; Table 2). The AUROC for RA diagnosis using individual miRNA ranged from 0.610 to 0.725, with miR-24-3p having the highest AUROC (Table 2). The combination of miR-24-3p, miR-26a-5p, and miR-125a-5p had the highest AUROC for RA diagnosis (AUROC = 0.747, 95% CI 0.683–0.810; Figure 1). The combination of miR-24-3p and miR-125a-5p, as reported18, had a similar AUROC for RA diagnosis (AUROC = 0.732, 95% CI 0.669–0.796).

Predictive capacity of the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p for RA diagnosis. Receiver-operating characteristic curve was made using the combination of plasma concentrations of miR-24-3p, miR-26a-5p, and miR-125a-5p. The area under the curve (AUROC) = 0.747 for diagnosis of RA with this combination of miRNA. miRNA: microRNA; RA: rheumatoid arthritis.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Predictive capacity of the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p for RA diagnosis. Receiver-operating characteristic curve was made using the combination of plasma concentrations of miR-24-3p, miR-26a-5p, and miR-125a-5p. The area under the curve (AUROC) = 0.747 for diagnosis of RA with this combination of miRNA. miRNA: microRNA; RA: rheumatoid arthritis.

View this table:
  • View inline
  • View popup
Table 2.

Candidate plasma microRNA (miRNA) concentrations in RA versus control plasma and area under the receiver-operating characteristic curve for RA diagnosis. miRNA concentrations presented as mean ± SD.

Comparing patients with RA who were RF-negative to control subjects, all miRNA were significantly elevated (all p < 0.003) except for miR-125a-5p (Supplementary Table 3, available online at jrheum.org). Moreover, miR-24-3p maintained the highest AUROC for RA diagnosis (AUROC = 0.772, 95% CI 0.688-0.857; Supplementary Table 3, and Supplementary Figure 1, available online at jrheum.org), although the combination of miR-24-3p, miR-26a-5p, and miR-125a-5p was similar (AUROC = 0.764, 95% CI 0.680–0.848).

Relationship to disease-related factors and medications in miRNA expression

We evaluated the utility of the 7 candidate miRNA for use as biomarkers of disease activity. Only miR-155-5p was weakly inversely correlated with swollen joint count in patients with RA (ρ −0.174, p = 0.02), and no other miRNA were correlated with DAS28 score, tender joint count, global health score, ESR, or CRP (all p > 0.08; Supplementary Table 4, available online at jrheum.org). Moreover, medication use including MTX, leflunomide, hydroxychloroquine, anti-tumor necrosis factor (TNF)-α agents, corticosteroids, and nonsteroidal antiinflammatory drugs were not associated with altered concentrations of any of the 7 miRNA evaluated (all p > 0.1).

Relationship to subclinical atherosclerosis and CV risk factors in miRNA expression

We next determined whether these 7 miRNA were associated with cardiovascular risk factors in patients with RA. None of the 7 miRNA were associated with coronary artery calcium score in RA (all p > 0.1; Supplementary Table 5). We found that miR-26a-5p was weakly associated with Framingham risk score (ρ 0.150, p = 0.05). There was a weak association with systolic blood pressure for miR-125a-5p (ρ 0.198, p = 0.01), but none with the diagnosis of hypertension (all p > 0.1). Two miRNA, miR-15a-5p and miR-24-3p, were modestly associated with waist circumference (ρ 0.185, p = 0.02 for miR-15a-5p; and ρ 0.208, p = 0.01 for miR-24-3p; Supplementary Table 5, available online at jrheum.org). None of the candidate miRNA were associated with traditional lipid profile (total cholesterol, LDL-C, high-density lipoprotein cholesterol, or triglycerides), smoking status, degree of insulin resistance (HOMA), or diabetes in patients with RA (all p > 0.05).

DISCUSSION

We found that miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p concentrations were elevated in the plasma of patients with RA. The combination of miR-24-3p, miR-26a-5p, and miR-125a-5p performed best to differentiate between patients with RA and control subjects, although the performance of the other miRNA did not differ meaningfully from these. Among RF-negative patients, miR-24-3p was a strong marker of RA. Among the miRNA tested, only miR-155-5p was weakly inversely associated with RA disease activity (swollen joint count). Moreover, there was little to no association between the plasma concentrations of the candidate miRNA and subclinical atherosclerosis or cardiovascular risk factors.

Our findings are consistent with a study by Murata, et al in which concentrations of miR-24-3p and miR-125a-5p had the best diagnostic utility for RA, and miR-26a-5p was also helpful18. However, we found that miR-24-3p rather than miR-125a-5p or a combination of miRNA was a better diagnostic tool in seronegative RA, which differs slightly from the previous study, which found that miR-125a-5p or the combination of miR-24-3p and miR-125a-5p was more accurate than miR-24-3p alone in seronegative (anticitrullinated peptide antibody) RA18. Comparing the current study with Murata, et al18, the fold increase comparing RA to control subjects in miR-24-3p was 3.5 in the current study and 3.75 in the prior study; the fold change in miR-26a-5p was 1.8 in the current study and 2.85 in the prior study; and the fold change in miR-125a-5p was 1.2 in the current study and 2.7 in the prior study. In the same study, plasma concentrations of miR-125a-5p did not correlate with indices of inflammation or disease activity, consistent with our findings.

In contrast to our results, miR-24-3p was positively correlated with some indices of disease activity including CRP, global health, and DAS28, but not ESR or tender or swollen joint count18. The previous study18 selected initial candidate miRNA from profiling results of a very small number of subjects (3 patients with RA and 3 control subjects); thus, important miRNA may not have been identified and studied. Therefore, we examined miRNA that were most strongly associated with RA in the previous study and also selected additional candidate miRNA that have been identified as having biological relevance to RA.

Two smaller studies compared selected circulating miRNA in patients with RA and control subjects. One included 30 patients with RA, 30 patients with osteoarthritis, and 30 healthy control subjects in a study measuring plasma miRNA8, and the second included 34 patients with treatment-naive early RA, 28 patients with late RA, and 16 healthy control subjects in a study measuring serum miRNA31. Both studies found that miR-146a-5p, miR-155-5p, and miR-223-3p levels were not different in patients with established RA compared to control subjects; however, both of these studies compared RA and control subjects without age- or sex-matching (e.g., about 15–18–year mean age difference between groups in both studies), and these factors may alter circulating miRNA32,33. Also, there have been problems with the reproducibility of findings with miR-146a-5p, miR-155-5p, and miR-223-3p in other studies. For example, in another inflammatory autoimmune disease, systemic lupus erythematosus, findings with plasma miR-146a-5p and miR-223-3p were not replicated in exploratory and validation cohorts34. Moreover, the relatively low abundance of plasma miR-155-5p may make it less reproducible across studies.

A recent study evaluated miRNA as possible predictors of response to therapy in RA35. Microarrays of miRNA were performed on sera of 10 patients with RA before and 6 months after starting disease-modifying antirheumatic drug (DMARD) or anti-TNF-α therapy. A subset of differentially expressed miRNA with relevance to inflammation, immune response, musculoskeletal system, or connective tissue were chosen to validate in a larger cohort of 85 patients with RA on paired serum samples. In this study, miR-146a-5p and miR-223-3p, among others, were significantly increased after DMARD/anti-TNF-α therapy, and miR-223-3p (along with miR-23) were predictors of response35.

The plasma miRNA that were most strongly associated with RA in our study (miR-24-3p, miR-26a-5p, and miR-125a-5p) appear to be reproducible18 and relevant to processes underlying RA. The miR-24-3p mediates plasma cell survival and is increased with plasma cell exposure to IL-614. Thus, miR-24-3p may contribute to RA by maintaining autoreactive plasma cells. One factor that may contribute to the high plasma levels of miR-26a-5p, miR-155-5p, and miR-146a-5p in patients with RA is increased IL-17–producing T cells16. Within macrophages, miR-125a-5p may have a role in modulating the inflammatory response. For example, in mouse bone marrow–derived macrophages, activation of Toll-like receptors 2 and 4 increased miR-125a-5p expression, and miR-125a-5p promoted an antiinflammatory cell phenotype36. Conversely, miR-125a-5p amplified the inflammatory response by repressing a negative regulator of NF-κB signaling in human THP-1 cells37.

The other plasma miRNA examined, which were elevated among patients with RA, also have important biologic functions in RA. One of the most widely studied is miR-146a-5p, which is increased in many cell types in RA such as synovial fibroblasts, peripheral blood mononuclear cells, CD4+ T cells, and Th17 cells, and acts as a negative regulator of nuclear factor-κB (NF-κB) activation (reviewed38). Another is miR-155-5p, a major regulator of B cell development and function, T cell dependent antibody responses, and T cell functions (reviewed39). Also, miR-223-3p modifies inflammation through several pathways, by decreasing monocyte IL-1b production and T cell IL-10 production (reviewed39,40).

In addition to their association with RA and inflammation, many of the miRNA we examined have a relationship to cardiovascular disease. Two key examples are miR-223-3p and miR-146a-5p. The miRNA miR-223-3p decreases cholesterol biosynthesis and enhances cholesterol efflux41. Moreover, delivery of miR-223-3p to endothelial cells decreased adhesion molecule expression42, a key factor in the development of atherosclerosis. Concentrations of miR-146a-5p were increased in the plasma and peripheral blood mononuclear cells of patients with acute coronary syndrome43, and miR-146a-5p affects endothelial function by regulation of nitric oxide production44. Nevertheless, these plasma miRNA were not associated with coronary artery calcium score.

Our study has some limitations. For example, we used a candidate miRNA approach to evaluate key miRNA thought to be important in the development of RA. A drawback of this method is that the miRNA field is rapidly expanding; therefore, potentially important miRNA were likely not included. Also, we did not study patients with other inflammatory autoimmune diseases such as systemic lupus erythematosus or psoriatic arthritis, to determine whether the miRNA examined here may differentiate between RA and other inflammatory autoimmune diseases. Future studies to evaluate this will be interesting, particularly given our findings in seronegative RA, a condition in which alternative diagnoses are often considered and an additional diagnostic tool would be very useful.

The miRNA miR-15a-5p, miR-24-3p, miR-26a-5p, miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-223-3p are all elevated in the plasma of patients with RA. The strongest diagnostic accuracy for RA exists in miR-24-3p, miR-26a-5p, and miR-125a-5p, and miR-24-3p had the strongest diagnostic accuracy for seronegative RA. Among the candidate miRNA evaluated, miR-155-5p was inversely associated with swollen joint count. None of the candidate miRNA were associated with coronary artery atherosclerosis in RA.

ONLINE SUPPLEMENT

Supplementary data for this article are available online at jrheum.org.

Footnotes

  • Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

  • Accepted for publication June 4, 2015.

REFERENCES

  1. 1.↵
    1. Baek D,
    2. Villen J,
    3. Shin C,
    4. Camargo FD,
    5. Gygi SP,
    6. Bartel DP
    . The impact of microRNAs on protein output. Nature 2008;455:64–71.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Bartel DP
    . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bartel DP
    . MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215–33.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Valadi H,
    2. Ekstrom K,
    3. Bossios A,
    4. Sjostrand M,
    5. Lee JJ,
    6. Lotvall JO
    . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654–9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hunter MP,
    2. Ismail N,
    3. Zhang X,
    4. Aguda BD,
    5. Lee EJ,
    6. Yu L,
    7. et al.
    Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008;3:e3694.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Vickers KC,
    2. Palmisano BT,
    3. Shoucri BM,
    4. Shamburek RD,
    5. Remaley AT
    . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423–33.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Arroyo JD,
    2. Chevillet JR,
    3. Kroh EM,
    4. Ruf IK,
    5. Pritchard CC,
    6. Gibson DF,
    7. et al.
    Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011;108:5003–8.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Murata K,
    2. Yoshitomi H,
    3. Tanida S,
    4. Ishikawa M,
    5. Nishitani K,
    6. Ito H,
    7. et al.
    Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010;12:R86.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mitchell PS,
    2. Parkin RK,
    3. Kroh EM,
    4. Fritz BR,
    5. Wyman SK,
    6. Pogosova-Agadjanyan EL,
    7. et al.
    Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513–8.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Myllykangas-Luosujarvi RA,
    2. Aho K,
    3. Isomaki HA
    . Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995;25:193–202.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pincus T,
    2. Sokka T,
    3. Wolfe F
    . Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234–6.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Cimmino A,
    2. Calin GA,
    3. Fabbri M,
    4. Iorio MV,
    5. Ferracin M,
    6. Shimizu M,
    7. et al.
    miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Nagata Y,
    2. Nakasa T,
    3. Mochizuki Y,
    4. Ishikawa M,
    5. Miyaki S,
    6. Shibuya H,
    7. et al.
    Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum 2009;60:2677–83.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Gabler J,
    2. Wittmann J,
    3. Porstner M,
    4. Renz H,
    5. Jack HM,
    6. Abram M,
    7. et al.
    Contribution of microRNA 24-3p and Erk1/2 to interleukin-6-mediated plasma cell survival. Eur J Immunol 2013;43:3028–37.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Haneklaus M,
    2. Gerlic M,
    3. Kurowska-Stolarska M,
    4. Rainey AA,
    5. Pich D,
    6. McInnes IB,
    7. et al.
    Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012;189:3795–9.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Niimoto T,
    2. Nakasa T,
    3. Ishikawa M,
    4. Okuhara A,
    5. Izumi B,
    6. Deie M,
    7. et al.
    MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010;11:209.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lopez-Pedrera C,
    2. Perez-Sanchez C,
    3. Ramos-Casals M,
    4. Santos-Gonzalez M,
    5. Rodriguez-Ariza A,
    6. Cuadrado MJ
    . Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. Clin Dev Immunol 2012;2012:974648.
    OpenUrlPubMed
  18. 18.↵
    1. Murata K,
    2. Furu M,
    3. Yoshitomi H,
    4. Ishikawa M,
    5. Shibuya H,
    6. Hashimoto M,
    7. et al.
    Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One 2013;8:e69118.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Duroux-Richard I,
    2. Jorgensen C,
    3. Apparailly F
    . What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum 2012;64:11–20.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Condorelli G,
    2. Latronico MV,
    3. Cavarretta E
    . microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014;63:2177–87.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Madrigal-Matute J,
    2. Rotllan N,
    3. Aranda JF,
    4. Fernandez-Hernando C
    . MicroRNAs and atherosclerosis. Curr Atheroscler Rep 2013;15:322.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Chung CP,
    2. Oeser A,
    3. Raggi P,
    4. Gebretsadik T,
    5. Shintani AK,
    6. Sokka T,
    7. et al.
    Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045–53.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Prevoo ML,
    2. van ‘t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL
    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Wilson PW,
    2. D’Agostino RB,
    3. Levy D,
    4. Belanger AM,
    5. Silbershatz H,
    6. Kannel WB
    . Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Chung CP,
    2. Oeser A,
    3. Avalos I,
    4. Gebretsadik T,
    5. Shintani A,
    6. Raggi P,
    7. et al.
    Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006;8:R186.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Matthews DR,
    2. Hosker JP,
    3. Rudenski AS,
    4. Naylor BA,
    5. Treacher DF,
    6. Turner RC
    . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Agatston AS,
    2. Janowitz WR,
    3. Hildner FJ,
    4. Zusmer NR,
    5. Viamonte M Jr,
    6. Detrano R
    . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Shipley GL
    . The MIQE guidelines uncloaked. PCR troubleshooting and optimization: the essential guide; 2011. [Internet. Accessed June 18, 2015.] Available from: www.gene-quantification.com/shipley-miqe-chapter-8-2011.pdf
  30. 30.↵
    1. Chung CP,
    2. Oeser A,
    3. Solus JF,
    4. Avalos I,
    5. Gebretsadik T,
    6. Shintani A,
    7. et al.
    Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008;196:756–63.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Filkova M,
    2. Aradi B,
    3. Senolt L,
    4. Ospelt C,
    5. Vettori S,
    6. Mann H,
    7. et al.
    Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis 2014;73:1898–904.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Simon LM,
    2. Edelstein LC,
    3. Nagalla S,
    4. Woodley AB,
    5. Chen ES,
    6. Kong X,
    7. et al.
    Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 2014;123:e37–45.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Meder B,
    2. Backes C,
    3. Haas J,
    4. Leidinger P,
    5. Stahler C,
    6. Grossmann T,
    7. et al.
    Influence of the confounding factors age and sex on microRNA profiles from peripheral blood. Clin Chem 2014;60:1200–8.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Carlsen AL,
    2. Schetter AJ,
    3. Nielsen CT,
    4. Lood C,
    5. Knudsen S,
    6. Voss A,
    7. et al.
    Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum 2013;65:1324–34.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Castro-Villegas C,
    2. Perez-Sanchez C,
    3. Escudero A,
    4. Filipescu I,
    5. Verdu M,
    6. Ruiz-Limon P,
    7. et al.
    Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res Ther 2015;17:49.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Banerjee S,
    2. Cui H,
    3. Xie N,
    4. Tan Z,
    5. Yang S,
    6. Icyuz M,
    7. et al.
    miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem 2013;288:35428–36.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Graff JW,
    2. Dickson AM,
    3. Clay G,
    4. McCaffrey AP,
    5. Wilson ME
    . Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem 2012;287:21816–25.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Chan EK,
    2. Ceribelli A,
    3. Satoh M
    . MicroRNA-146a in autoimmunity and innate immune responses. Ann Rheum Dis 2013;72 Suppl 2:ii90–5.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Ammari M,
    2. Jorgensen C,
    3. Apparailly F
    . Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2013;25:225–33.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Fulci V,
    2. Scappucci G,
    3. Sebastiani GD,
    4. Giannitti C,
    5. Franceschini D,
    6. Meloni F,
    7. et al.
    miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 2010;71:206–11.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Vickers KC,
    2. Landstreet SR,
    3. Levin MG,
    4. Shoucri BM,
    5. Toth CL,
    6. Taylor RC,
    7. et al.
    MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 2014;111:14518–23.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Tabet F,
    2. Vickers KC,
    3. Cuesta Torres LF,
    4. Wiese CB,
    5. Shoucri BM,
    6. Lambert G,
    7. et al.
    HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun 2014;5:3292.
    OpenUrlPubMed
  43. 43.↵
    1. Guo M,
    2. Mao X,
    3. Ji Q,
    4. Lang M,
    5. Li S,
    6. Peng Y,
    7. et al.
    miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome. Immunol Cell Biol 2010;88:555–64.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Sun X,
    2. Belkin N,
    3. Feinberg MW
    . Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep 2013;15:372.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 42, Issue 10
1 Oct 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi, C. Michael Stein
The Journal of Rheumatology Oct 2015, 42 (10) 1746-1751; DOI: 10.3899/jrheum.150232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi, C. Michael Stein
The Journal of Rheumatology Oct 2015, 42 (10) 1746-1751; DOI: 10.3899/jrheum.150232
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ONLINE SUPPLEMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Keywords

RHEUMATOID ARTHRITIS
microRNA
ATHEROSCLEROSIS
DISEASE ACTIVITY
DIAGNOSIS
CARDIOVASCULAR RISK

Related Articles

Cited By...

More in this TOC Section

  • Validation of Handheld Ultrasound Devices for Point-of-Care Use in Rheumatology: Focus on Synovitis, Doppler Activity, Erosions, and Tendon Lesions
  • Persistent Opioid Exposure in Older Adults With Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing
  • What Makes Axial Spondyloarthritis Difficult to Manage? A Qualitative Study of Patient and Rheumatologist Perspectives
Show more Article

Similar Articles

Keywords

  • rheumatoid arthritis
  • microRNA
  • ATHEROSCLEROSIS
  • disease activity
  • diagnosis
  • cardiovascular risk

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire